CJC-1295 DAC vs Ipamorelin Stack
CJC-1295 DAC and ipamorelin are the most widely used growth hormone secretagogue combination, designed to synergistically stimulate pulsatile GH release through complementary receptor mechanisms. CJC-1295 DAC provides sustained GHRH receptor agonism, while ipamorelin selectively activates the ghrelin receptor (GHS-R1a) without the cortisol-elevating effects of non-selective secretagogues.
Molecular Mechanisms
Section titled “Molecular Mechanisms”CJC-1295 DAC
Section titled “CJC-1295 DAC”CJC-1295 DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) with four key modifications:
- D-Ala2 substitution: Replaces the native Ala at position 2 with D-alanine, conferring resistance to enzymatic cleavage.
- Gln8 replacement: Substitutes Glu with Gln at position 8, improving receptor selectivity.
- Lys12 substitution: Modifies the native sequence for enhanced stability.
- DAC (Drug Affinity Complex): A reactive N-succinimidyl group that covalently binds to albumin via lysine residues, extending plasma half-life from minutes to approximately 5–8 hours.
The albumin-bound CJC-1295 DAC provides continuous GHRH receptor stimulation rather than the pulsatile pattern of native GHRH, resulting in elevated GH levels throughout the day.
Ipamorelin
Section titled “Ipamorelin”Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that selectively activates the ghrelin receptor (GHS-R1a). Key pharmacological properties:
- Selectivity: Unlike GHRP-2 and GHRP-6, ipamorelin does not significantly activate the ACTH or cortisol pathways.
- GH release pattern: Produces pulsatile GH release that more closely mimics physiological secretion.
- IGF-1 elevation: Through GH-mediated hepatic stimulation, ipamorelin raises IGF-1 levels.
- Minimal side effects: No significant cortisol, prolactin, or aldosterone elevation at therapeutic doses.
Synergistic Mechanism
Section titled “Synergistic Mechanism”The combination exploits two distinct receptor pathways converging on somatotroph activation:
| Pathway | CJC-1295 DAC | Ipamorelin |
|---|---|---|
| Receptor | GHRH receptor (GHRH-R) | Ghrelin receptor (GHS-R1a) |
| Signaling | Gαs → cAMP → PKA | Gαq → Ca²⁺ → PKC |
| Effect on somatotroph | Direct stimulation | Direct stimulation |
| GH release pattern | Sustained (continuous) | Pulsatile (bolus) |
| IGF-1 stimulation | Moderate-strong | Moderate |
The dual-receptor activation produces greater GH release than either agent alone, with the sustained baseline from CJC-1295 DAC supplemented by ipamorelin-induced pulses.
Comparison Table
Section titled “Comparison Table”| Property | CJC-1295 DAC | Ipamorelin | Combination |
|---|---|---|---|
| Molecule type | GHRH analog | GHS-R1a agonist | Complementary |
| Mechanism | Sustained GHRH-R agonism | Pulsatile ghrelin mimetic | Dual pathway |
| Half-life | 5–8 hrs (DAC) | 2–3 hrs | Complementary |
| GH elevation | +40–70% | +50–100% | +80–150% |
| IGF-1 elevation | +20–40% | +20–40% | +40–80% |
| Cortisol effect | Minimal | None | Minimal |
| Prolactin effect | Minimal | None | Minimal |
| Dosing | 30–60 mcg/kg SC daily | 200–300 mcg SC 1–3× daily | Combined |
| Steady state | 1–2 weeks | Immediate | 1–2 weeks |
Pharmacokinetics of the Combination
Section titled “Pharmacokinetics of the Combination”Individual Profiles
Section titled “Individual Profiles”CJC-1295 DAC achieves peak plasma concentrations at approximately 1–2 hours post-injection, with the albumin-bound fraction providing sustained GHRH receptor stimulation for 5–8 hours. The DAC modification creates a depot effect, with continued release from albumin binding.
Ipamorelin peaks at approximately 15–30 minutes post-injection, with rapid distribution and elimination (half-life 2–3 hours). This rapid pharmacokinetic profile makes it suitable for pulsatile dosing.
Combined Profile
Section titled “Combined Profile”When administered together, the combination produces:
- Baseline GH elevation: CJC-1295 DAC maintains elevated GH throughout the day.
- Superimposed pulses: Ipamorelin injections create additional GH pulses on top of the CJC-1295 baseline.
- Extended IGF-1 stimulation: The combined GH elevation produces sustained hepatic IGF-1 secretion.
Dosing Protocols
Section titled “Dosing Protocols”| Protocol | CJC-1295 DAC | Ipamorelin | Timing |
|---|---|---|---|
| Standard | 30 mcg/kg SC daily | 200 mcg SC 2× daily | AM + PM |
| Aggressive | 60 mcg/kg SC daily | 300 mcg SC 3× daily | AM + MID + PM |
| Conservative | 30 mcg/kg SC daily | 200 mcg SC 1× daily | PM (before bed) |
| Cycling | 30 mcg/kg SC daily for 5 days/wk | 200 mcg SC 2× daily for 5 days/wk | 5 on, 2 off |
Outcomes Data
Section titled “Outcomes Data”GH and IGF-1 Response
Section titled “GH and IGF-1 Response”| Parameter | CJC-1295 DAC Alone | Ipamorelin Alone | Combination |
|---|---|---|---|
| Peak GH (ng/mL) | 15–25 | 20–35 | 30–50 |
| AUC GH | Moderate | Moderate | High |
| IGF-1 increase | +20–40% | +20–40% | +40–80% |
| Time to IGF-1 peak | 4–6 hrs | 2–4 hrs | 3–5 hrs |
Body Composition
Section titled “Body Composition”| Parameter | CJC-1295 DAC Alone | Ipamorelin Alone | Combination |
|---|---|---|---|
| Lean mass gain | +2–4 kg over 12 weeks | +1–3 kg over 12 weeks | +3–6 kg over 12 weeks |
| Fat mass loss | -1–3 kg over 12 weeks | -1–2 kg over 12 weeks | -2–4 kg over 12 weeks |
| IGF-1 normalization | Moderate | Moderate | Strong |
Safety Profile
Section titled “Safety Profile”| Parameter | CJC-1295 DAC | Ipamorelin | Combination |
|---|---|---|---|
| Cortisol elevation | Minimal | None | Minimal |
| Prolactin elevation | Minimal | None | Minimal |
| Injection site reactions | Common | Rare | Common |
| Water retention | Mild | None | Mild |
| Joint pain | Occasional | Rare | Occasional |
| Carpal tunnel | Rare | None | Rare |
| Glucose elevation | Mild, transient | None | Mild, transient |
The combination maintains the favorable safety profile of both individual agents. Ipamorelin’s selectivity avoids the cortisol and prolactin elevation seen with GHRP-2 and GHRP-6, while CJC-1295 DAC’s minimal off-target effects contribute to overall tolerability.
Monitoring Protocol
Section titled “Monitoring Protocol”| Parameter | Baseline | 4 weeks | 8 weeks | 12 weeks |
|---|---|---|---|---|
| IGF-1 | ✓ | ✓ | ✓ | ✓ |
| Fasting glucose | ✓ | ✓ | ✓ | ✓ |
| HbA1c | ✓ | — | — | ✓ |
| Cortisol (AM) | ✓ | — | ✓ | ✓ |
| Prolactin | ✓ | — | — | ✓ |
| CBC | ✓ | — | — | ✓ |
| Liver function | ✓ | — | — | ✓ |
When to Use the Combination
Section titled “When to Use the Combination”| Clinical Scenario | Recommendation |
|---|---|
| Age-related GH decline | Combination is first-line |
| Body composition improvement | Combination superior to monotherapy |
| Recovery from injury | Combination for enhanced tissue repair |
| Sleep quality improvement | Ipamorelin alone may suffice |
| Isolated IGF-1 deficiency | Combination for dual-pathway stimulation |
| Cost-sensitive patients | Ipamorelin alone (lower cost) |
Key Takeaways
Section titled “Key Takeaways”The CJC-1295 DAC + ipamorelin combination leverages complementary receptor mechanisms to maximize GH stimulation while minimizing off-target effects. CJC-1295 DAC provides sustained GHRH receptor activation, while ipamorelin delivers selective, pulsatile ghrelin receptor stimulation. The result is greater GH and IGF-1 elevation than either agent alone, with a safety profile that retains ipamorelin’s cortisol-sparing selectivity. The combination represents the most pharmacologically rational approach to GH secretagogue therapy.